What to ask your oncologist about clinical trials

"Are there any trials we should be looking at?" is a fair question, but it rarely gets a useful answer on its own. Oncologists are weighing dozens of factors you can't see. The way to get a real conversation going is to ask specific questions — ideally about specific trials you've already found. (If you haven't started looking yet, our guide on staying on top of new cancer research covers where to look first.)

None of this is medical advice. It's a list of questions to help you have a more productive conversation with the people who actually know the case.

Eligibility: would this person even qualify?

Most trials are ruled out before treatment ever comes up, simply because of who they accept. Ask:

• Does the diagnosis and subtype match? Many trials accept only one histology or molecular subtype.
• Do the biomarkers fit? A trial may require — or exclude — a specific mutation or marker (EGFR, KRAS, HER2, PD-L1, MSI status, and so on).
• Does the prior treatment history fit? Trials are often written for a specific "line" — first-line, second-line, or after a particular drug has failed.
• Are there disqualifying conditions? Other diagnoses, organ function, or recent treatments can exclude someone.

Phase: what is the trial actually testing?

A trial's phase tells you what question it's trying to answer — and that shapes the trade-offs:

• Phase I is mostly about safety and dosing. Smaller, earlier, more uncertain.
• Phase II starts to look at whether the treatment works for a condition.
• Phase III compares it against the current standard of care, usually at larger scale.

Ask your oncologist how the phase changes what to expect — including whether there's a chance of being placed in a control or standard-of-care group rather than receiving the experimental treatment.

Logistics: can your family actually do this?

Trials fail families on practicalities as often as on medicine. Ask:

• Where is it, and how often would we travel? Some trials require frequent on-site visits.
• What's the time commitment? Extra scans, bloodwork, and appointments add up.
• What's covered, and what isn't? The trial may cover the drug but not travel, lodging, or routine care costs.
• Is it currently recruiting? Listings go stale; a trial can be "active" but closed to new participants.

Risks, benefits, and exit

• What are the known and possible side effects?
• What's the realistic hoped-for benefit — and what does success look like in this trial?
• Can we leave if we need to, and what happens to care afterward?
• Would joining this trial close off other options later?

The best question you can bring isn't "what should we do?" — it's "here's a specific trial; would this person qualify, and is it worth pursuing?" Specific beats open-ended every time.

Bring a specific list, not a vague worry

Walk in with the trial identifiers (the NCT numbers from ClinicalTrials.gov), why you flagged each one, and these questions. It respects everyone's time and turns an anxious "are we missing something?" into a focused, answerable conversation.

← Back to the blog  ·  Read: how to stay on top of new research →